Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Aspire Health vs Curve

Aspire Health
Graded #346

Lower grade

vs+2.6999999999999957
Curve
Graded #280

Higher grade

The verdict

Curve takes it — 61.9/100 to 59.2/100.

Curve grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Curve (Try Curve LLC) is a telehealth platform offering compounded semaglutide and tirzepatide, prescribed by Beluga Health providers licensed in all 50 states and dispensed by VialsRx, a US 503A…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueCurve +13
45
58
Dose & formulationCurve +11
53
64
Clinical oversightAspire Health +16
84
68
Labs & monitoringAspire Health +14
66
52
FulfillmentCurve +36
61
97
Contract termsAspire Health +21
41
20
Aspire Health · left barCurve · right bar

The numbers

MetricAspire HealthCurve
WeighScore59.2/10061.9/100
GradeCC
Scorecard rank#346#280
SemaglutideNot disclosed$175/mo (compounded)
TirzepatideNot disclosed$225/mo (compounded)
CoverageCoverage not publishedAll 50 states
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
Aspire Health

Graded #346 · C

Strengths

  • Both compounded and brand-name options (Wegovy + Zepbound) — rare among GLP-1 telehealth providers
  • Lab orders with interpretation included in LoseIt membership — not billed separately
  • Named clinical team: founded by Jenni Haan, MPAS, PA-C (18+ years experience) with four additional credentialed providers
  • Slimpossible app + secure messaging for ongoing support between provider visits
  • HSA/FSA accepted; Cherry third-party financing available for patients needing payment plans

Where it loses points

  • Membership fee ($75/month) stacks on top of separately billed medication — total spend $205–$524/month depending on dose
  • No LegitScript certification or independent third-party accreditation disclosed
  • States served not publicly listed; availability depends on individual provider licensure
  • All medication sales are final once shipped; consultation fee non-refundable once completed
  • Compounding pharmacy partner not named on any public page
Curve

Graded #280 · C

Strengths

  • Offers both compounded semaglutide and tirzepatide, with every dose priced the same so cost does not rise as you titrate up.
  • LegitScript-certified (seal #51079066) and names both its 503A compounding pharmacy, VialsRx, and its provider network, Beluga Health.
  • Transparent tiered pricing with a real month-to-month option; consultation, medication, and free expedited shipping included, no membership.
  • Available in all 50 states with same-day provider review; no insurance needed and HSA/FSA accepted.

Where it loses points

  • Very new (2026 launch) with a thin track record; the site still shows a Webflow template credit and a leftover Cora reference in its Terms.
  • The cheapest headline rates ($99 semaglutide / $135 tirzepatide) require a 12-month prepay; true month-to-month is $175 and $225.
  • Both product pages currently display an out-of-stock status, so availability may be inconsistent.
  • Compounded medications are not FDA-approved or therapeutically equivalent to Ozempic, Wegovy, Mounjaro, or Zepbound.

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard